Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Davy-Mendez T, Napravnik S, Zakharova O, Kuruc J, Gay C, Hicks CB, Mcgee KS, Eron JJ.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):510-518. doi: 10.1097/QAI.0000000000001843.

PMID:
30142143
2.

A Wake-up Call for Human Immunodeficiency Virus (HIV) Providers: Obstructive Sleep Apnea in People Living With HIV.

Owens RL, Hicks CB.

Clin Infect Dis. 2018 Jul 18;67(3):472-476. doi: 10.1093/cid/ciy217.

PMID:
29746617
3.

Diminished physical function in older HIV-infected adults in the Southeastern U.S. despite successful antiretroviral therapy.

Khoury AL, Morey MC, Wong TC, McNeil DL, Humphries B, Frankey K, Pieper CF, Hicks CB, Huffman K, McKellar MS.

PLoS One. 2017 Jun 29;12(6):e0179874. doi: 10.1371/journal.pone.0179874. eCollection 2017.

4.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD, McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis DM.

AIDS Res Hum Retroviruses. 2018 Jan;34(1):111-122. doi: 10.1089/aid.2017.0071. Epub 2017 Jun 21.

5.

Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.

Gay CL, Willis SJ, Cope AB, Kuruc JD, McGee KS, Sebastian J, Crooks AM, McKellar MS, Margolis DM, Fiscus SA, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium.

AIDS. 2016 Nov 28;30(18):2815-2822.

6.

Syphilis on the Rise: What Went Wrong?

Clement ME, Hicks CB.

JAMA. 2016 Jun 7;315(21):2281-3. doi: 10.1001/jama.2016.7073. No abstract available.

PMID:
27272579
7.

History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke.

Okeke NL, Hicks CB, McKellar MS, Fowler VG Jr, Federspiel JJ.

J Infect Dis. 2016 Jun 15;213(12):1955-61. doi: 10.1093/infdis/jiw082. Epub 2016 Mar 3.

8.

Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.

Okeke NL, Chin T, Clement M, Chow SC, Hicks CB.

AIDS Care. 2016;28(4):475-82. doi: 10.1080/09540121.2015.1099602. Epub 2015 Oct 19.

9.

Fever and Rash in a Patient With Hepatitis.

Clement ME, Okeke NL, Hicks CB.

JAMA. 2015 Jul 28;314(4):400-1. doi: 10.1001/jama.2015.3401. No abstract available.

10.

Treatment of late-stage syphilis--reply.

Clement ME, Okeke NL, Hicks CB.

JAMA. 2015 Mar 3;313(9):969-70. doi: 10.1001/jama.2015.0675. No abstract available.

PMID:
25734743
11.

Last Word on Viewpoint: The ongoing need for good physiological investigation: Obstructive sleep apnea in HIV patients as a paradigm.

Darquenne C, Hicks CB, Malhotra A.

J Appl Physiol (1985). 2015 Jan 15;118(2):251. doi: 10.1152/japplphysiol.00984.2014. No abstract available.

12.

New resources for audiologists working with Hispanic patients: Spanish translations and cultural training.

Reel LA, Hicks CB, Ortiz N, Rodriguez A.

Am J Audiol. 2015 Mar;24(1):11-22. doi: 10.1044/2014_AJA-14-0027.

PMID:
25569165
13.

RPR and the serologic diagnosis of syphilis.

Clement ME, Hicks CB.

JAMA. 2014 Nov 12;312(18):1922-3. doi: 10.1001/jama.2014.2087. No abstract available.

PMID:
25387191
14.

Treatment of syphilis: a systematic review.

Clement ME, Okeke NL, Hicks CB.

JAMA. 2014 Nov 12;312(18):1905-17. doi: 10.1001/jama.2014.13259. Review.

PMID:
25387188
15.

VISION: a regional performance improvement initiative for HIV health care providers.

Bruno TO, Hicks CB, Naggie S, Wohl DA, Albrecht H, Thielman NM, Rabin DU, Layton S, Subramaniam C, Grichnik KP, Shlien A, Weyer D.

J Contin Educ Health Prof. 2014 Summer;34(3):171-8. doi: 10.1002/chp.21248.

PMID:
25258129
16.

The ongoing need for good physiological investigation: obstructive sleep apnea in HIV patients as a paradigm.

Darquenne C, Hicks CB, Malhotra A.

J Appl Physiol (1985). 2015 Jan 15;118(2):244-6. doi: 10.1152/japplphysiol.00656.2014. Epub 2014 Aug 21. No abstract available.

17.

Incident sexually transmitted infection as a biomarker for high-risk sexual behavior after diagnosis of acute HIV.

Cope AB, Crooks AM, Chin T, Kuruc JD, McGee KS, Eron JJ, Hicks CB, Hightow-Weidman LB, Gay CL.

Sex Transm Dis. 2014 Jul;41(7):447-52. doi: 10.1097/OLQ.0000000000000147.

18.

A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.

Goswami ND, Tsalik EL, Naggie S, Miller WC, Horton JR, Pfeiffer CD, Hicks CB.

Trials. 2014 Jan 22;15:31. doi: 10.1186/1745-6215-15-31.

19.

Updated recommendations on INSTI-based regimens for ART-naive patients.

Hicks CB.

J Watch AIDS Clin Care. 2013 Dec;25(12):89. No abstract available.

PMID:
26204591
20.

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

Hurt CB, Sebastian J, Hicks CB, Eron JJ.

Clin Infect Dis. 2014 Feb;58(3):423-31. doi: 10.1093/cid/cit697. Epub 2013 Oct 21.

21.

The awareness of doctoral-level professions among entering college students.

Donai JJ, Hicks CB, McCart M.

Am J Audiol. 2013 Dec;22(2):271-82.

PMID:
23824429
22.

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.

Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):505-8. doi: 10.1097/QAI.0b013e318285cd33.

23.

Acute HIV-1 infection in the Southeastern United States: a cohort study.

McKellar MS, Cope AB, Gay CL, McGee KS, Kuruc JD, Kerkau MG, Hurt CB, Fiscus SA, Ferrari G, Margolis DM, Eron JJ, Hicks CB; Duke-Unc Acute HIV Infection Consortium.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):121-8. doi: 10.1089/AID.2012.0064. Epub 2012 Sep 4.

24.

CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection.

Frahm MA, Picking RA, Kuruc JD, McGee KS, Gay CL, Eron JJ, Hicks CB, Tomaras GD, Ferrari G.

J Immunol. 2012 May 1;188(9):4289-96. doi: 10.4049/jimmunol.1103701. Epub 2012 Mar 28.

25.

Pre-exposure prophylaxis--one more tool for HIV prevention.

Person AK, Hicks CB.

Curr HIV Res. 2012 Mar;10(2):117-22. Review.

PMID:
22329517
26.

Growing the intense inhibitor class--Elvitegravir and Dolutegravir.

Hicks CB.

J Watch AIDS Clin Care. 2012 Jan;24(1):5-6. No abstract available.

PMID:
26223043
27.

HIV treatment as prevention--the time is now.

Hicks CB.

J Watch AIDS Clin Care. 2012 Jan;24(1):1. No abstract available.

PMID:
26223035
28.

Selective auditory attention in adults: effects of rhythmic structure of the competing language.

Reel LA, Hicks CB.

J Speech Lang Hear Res. 2012 Feb;55(1):89-104. doi: 10.1044/1092-4388(2011/10-0193). Epub 2011 Dec 22.

PMID:
22199199
29.

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.

Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B.

PLoS Pathog. 2011 Sep;7(9):e1002209. doi: 10.1371/journal.ppat.1002209. Epub 2011 Sep 29.

30.

Investigational antiretrovirals--the pipeline is not dry.

Hicks CB.

J Watch AIDS Clin Care. 2011 May;23(5):39. No abstract available.

PMID:
27652428
31.

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Wang D, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, Cai F, Perelson AS, Gao F.

J Virol. 2011 Jul;85(13):6403-15. doi: 10.1128/JVI.02389-10. Epub 2011 Apr 13.

32.

Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.

Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, McGee KS, Kerkau M, Sebastian J, Fiscus SA, Margolis DM, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium.

AIDS. 2011 Apr 24;25(7):941-9. doi: 10.1097/QAD.0b013e3283463c07.

33.

Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.

Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, Hazuda DJ, Gao F.

Antimicrob Agents Chemother. 2011 Mar;55(3):1114-9. doi: 10.1128/AAC.01492-10. Epub 2010 Dec 20.

34.

Cyclosporine in acute and early HIV infection.

Hicks CB.

J Watch AIDS Clin Care. 2010 Jun;22(6):54-5. No abstract available.

PMID:
20669362
36.

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.

Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, Schumacher JE, Hraber P, Giorgi EE, Bhattacharya T, Korber BT, Perelson AS, Eron JJ, Cohen MS, Hicks CB, Haynes BF, Markowitz M, Keele BF, Hahn BH, Shaw GM.

PLoS Pathog. 2010 May 13;6(5):e1000890. doi: 10.1371/journal.ppat.1000890.

37.
38.

Report from the 17th Conference on Retroviruses and Opportunistic Infections. Four antiretrovirals in one?

Hicks CB.

J Watch AIDS Clin Care. 2010 Apr;22(4):30-1. No abstract available.

PMID:
20480618
39.
40.
41.

Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS.

Naggie S, Hseih T, Reckleff J, Castellano J, Hicks CB.

Clin Infect Dis. 2009 Nov 15;49(10):1619-20. doi: 10.1086/644776. No abstract available.

PMID:
19857170
42.

HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection.

Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF.

J Immunol. 2009 Aug 15;183(4):2708-17. doi: 10.4049/jimmunol.0901068. Epub 2009 Jul 22.

43.

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, Gurley TC, Allgood S, Haynes BB, Vandergrift NA, Plonk S, Parker DC, Cohen MS, Tomaras GD, Goepfert PA, Shaw GM, Schmitz JE, Eron JJ, Shaheen NJ, Hicks CB, Liao HX, Markowitz M, Kelsoe G, Margolis DM, Haynes BF.

PLoS Med. 2009 Jul 7;6(7):e1000107. doi: 10.1371/journal.pmed.1000107. Epub 2009 Jul 7.

44.

Report from the 16th Conference on Retroviruses and Opportunistic Infections. Investigational pharmacologic boosters.

Hicks CB.

J Watch AIDS Clin Care. 2009 Apr;21(4):33-4. No abstract available.

PMID:
19548333
45.
46.

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF.

AIDS. 2009 May 15;23(8):897-906. doi: 10.1097/QAD.0b013e328329f97d.

47.

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; COL100758 Study Team.

AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403. doi: 10.1089/aid.2008.0231.

PMID:
19320570
48.

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.

AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75. doi: 10.1089/aid.2008.0217.

PMID:
19292590
49.

Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk?

Hicks CB.

AIDS Clin Care. 2008 Apr;20(4):29. No abstract available.

PMID:
19266668
50.

Supplemental Content

Loading ...
Support Center